GO
Loading...

Allergan Inc

More

  • Cramer: The lucrative journey of Allergan Monday, 17 Nov 2014 | 6:07 PM ET
    A clinical technician holds a syringe and a vial of Allergan Botox, produced by Allergan Inc.

    Jim Cramer reviews the acquisition of Allergan by Actavis to judge just how lucrative the deal could really be for shareholders.

  • *Baker Hughes rallies, Halliburton tumbles after deal. Shares of Baker Hughes, up 8.9 percent, and Allergan, up 5.3 percent, gave the S&P 500 its biggest boost after Halliburton said it would buy Baker Hughes and Allergan agreed to be bought by Actavis. "It shows the strength of the overall market that you could have this recession news out of Japan, and yet have the...

  • Stocks little moved; S&P 500 at record-high close Monday, 17 Nov 2014 | 4:00 PM ET
    Trader on the floor of the New York Stock Exchange.

    Stocks fell Monday after data had Japan unexpectedly falling into a recession.

  • Ackman's win-win  Monday, 17 Nov 2014 | 3:18 PM ET

    Actavis announced it will acquire Allergan for $66 billion. Marc LoPresti of Lopresti Law Group, and Michael Farr of Farr, Miller & Washington, discuss Pershing Square Bill Ackman's actions.

  • Nov 17- Botox maker Allergan Inc on Monday accepted a $66 billion takeover bid from Actavis Plc, ending a seven-month hostile pursuit by activist investor William Ackman and Valeant Pharmaceuticals International Inc.. Besides the higher price tag, the Actavis deal came with only $400 million in R&D cuts for Allergan, far less than the $900 million decrease...

  • *Brent falls toward $78 as Japanese growth stalls. NEW YORK, Nov 17- Oil prices fell and global equity markets were mixed on Monday after news that Japan unexpectedly slipped into recession in the third quarter renewed concerns about the world economy, but merger activity and comment about European stimulus capped declines. Brent oil initially fell more than $1...

  • *Baker Hughes rallies, Halliburton tumbles after deal. Shares of Baker Hughes, up 10.2 percent, and Allergan, up 5.1 percent, led gains on the S&P 500 after Halliburton said it would buy Baker Hughes and Allergan agreed to be bought by Actavis. The largest percentage gainer on the S&P 500 was Baker Hughes, while the largest decliner was Halliburton, down 10.1 percent.

  • NEW YORK, Nov 17- Actavis will issue around US $27.5 bn of new debt to finance its US $66 bn acquisition of Botox-maker Allergan, but about half of it will be short-dated to help the company keep its investment-grade ratings. Both Moody's and Fitch said they would not downgrade Actavis to junk despite the increased debt, believing strong cash flow will enable it to...

  • Losing Allergan deals blow to Valeant reputation Monday, 17 Nov 2014 | 1:25 PM ET

    WINNIPEG/ NEW YORK Nov 17- The failure of Valeant Pharmaceuticals International Inc to buy Allergan Inc leaves it with nothing to show for a seven-month, bruising pursuit. Losing Allergan to Actavis PLC also hurts Valeant's deal-making reputation, said a source close to the company not authorized to speak publicly. Allergan's rebuff will embolden future...

  • Midday movers: Allergan, CarMax, CBS & more Monday, 17 Nov 2014 | 1:03 PM ET

    Some of Monday's midday movers:

  • NEW YORK, Nov 17- Hedge fund Omega Advisors expects to see the U.S. stock market's bull run continue into next year, fueled by steady economic growth and a corporate takeover boom. "My expectation is for the Standard& Poor's 500 to gain 7 percent to 9 percent in 2015," Steven Einhorn, Omega's vice chairman said on Monday. Omega, founded by Leon Cooperman two decades ago...

  • Hedge fund winners in Allergan deal  Monday, 17 Nov 2014 | 12:33 PM ET

    Actavis is buying Allergan for $66 billion. CNBC's Kate Kelly provides insight to speculation surrounding the benefit of the deal to Pershing Square's Bill Ackman.

  • *Baker Hughes rallies, Halliburton tumbles after deal. The M&A news partly offset the declines as Allergan agreed to be bought by Actavis while Halliburton said it would buy Baker Hughes. Allergan and Baker Hughes were the top point gainers on the S&P 500..

  • Done deal: Actavis buying Allergan for $66 billion Monday, 17 Nov 2014 | 11:55 AM ET
    Actavis pharmaceuticals.

    The deal beats the unsolicited bid last spring of above $50 billion from Valeant, which teamed with Bill Ackman.

  • *Baker Hughes rallies on Halliburton deal; crude futures fall. *DreamWorks shares slide as Hasbro talks stall. Merger and acquisition news offset the declines as Halliburton said it would buy Baker Hughes and Allergan agreed to be bought by Actavis.

  • Nov 17- Allergan Inc agreed to be bought by Actavis Plc for $66 billion, putting an end to a hostile bid by activist investor William Ackman and Valeant Pharmaceuticals International Inc.. The offer values Allergan at $219 per share and is $6 billion more than the price Valeant had last offered to pay. Allergan shares rose 6.6 percent to $211, earning Ackman a...

  • Nov 17- Valeant Pharmaceuticals International Inc Chief Executive Michael Pearson said on Monday that the company can't justify matching Actavis Plc's $219 per share bid for Allergan Inc..

  • Why Allergan never engaged Valeant  Monday, 17 Nov 2014 | 9:36 AM ET

    Allergan chairman & CEO David Pyott, explains why Allergan never engaged Valeant Pharmaceuticals and what's next for the newly combined companies.

  • Actavis CEO: Huge commitment to R&D  Monday, 17 Nov 2014 | 9:32 AM ET

    CNBC's Jim Cramer speaks to Brent Saunders, Actavis CEO, and David Pyott, Allergan chairman & CEO, about the growth and R&D budget of the combined companies going forward.

  • Actavis CEO: Allergan best run pharma company  Monday, 17 Nov 2014 | 9:30 AM ET

    CNBC's David Faber speaks to David Pyott, Allergan chairman & CEO, and Brent Saunders, Actavis CEO about their deal worth roughly $66 billion and what it means for shareholders.